KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Amortization - Deferred Charges (2016 - 2026)

Gsk has reported Amortization - Deferred Charges over the past 13 years, most recently at -$53.9 million for Q1 2026.

  • For Q1 2026, Amortization - Deferred Charges fell 167.6% year-over-year to -$53.9 million; the TTM value through Mar 2026 reached -$732.5 million, down 20.97%, while the annual FY2025 figure was -$343.2 million, N/A changed from the prior year.
  • Amortization - Deferred Charges for Q1 2026 was -$53.9 million at Gsk, up from -$343.2 million in the prior quarter.
  • Over five years, Amortization - Deferred Charges peaked at -$13.9 million in Q3 2023 and troughed at -$919.6 million in Q4 2022.
  • A 5-year average of -$234.6 million and a median of -$105.0 million in 2022 define the central range for Amortization - Deferred Charges.
  • Biggest five-year swings in Amortization - Deferred Charges: soared 73.13% in 2023 and later crashed 171.62% in 2025.
  • Year by year, Amortization - Deferred Charges stood at -$919.6 million in 2022, then grew by 12.13% to -$808.0 million in 2023, then skyrocketed by 68.23% to -$256.7 million in 2024, then crashed by 33.69% to -$343.2 million in 2025, then skyrocketed by 84.29% to -$53.9 million in 2026.
  • Business Quant data shows Amortization - Deferred Charges for GSK at -$53.9 million in Q1 2026, -$343.2 million in Q4 2025, and -$45.9 million in Q3 2025.